These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

514 related articles for article (PubMed ID: 11994035)

  • 21. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. Progetto Pertosse Working Group.
    Greco D; Salmaso S; Mastrantonio P; Giuliano M; Tozzi AE; Anemona A; Ciofi degli Atti ML; Giammanco A; Panei P; Blackwelder WC; Klein DL; Wassilak SG
    N Engl J Med; 1996 Feb; 334(6):341-8. PubMed ID: 8538704
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Recommended or mandatory pertussis vaccination policy in developed countries: does the choice matter?
    Girard DZ
    Public Health; 2012 Feb; 126(2):117-22. PubMed ID: 22226337
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pertussis: History of the Disease and Current Prevention Failure.
    Kuchar E; Karlikowska-Skwarnik M; Han S; Nitsch-Osuch A
    Adv Exp Med Biol; 2016; 934():77-82. PubMed ID: 27256351
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The Global Pertussis Initiative: meeting report from the fourth regional roundtable meeting, France, April 14-15, 2010.
    Guiso N; Liese J; Plotkin S
    Hum Vaccin; 2011 Apr; 7(4):481-8. PubMed ID: 21389775
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Pertussis: a reemerging infection?].
    Kriz B; Fabiánová K; Maixnerová M; Benes C; Malý M
    Epidemiol Mikrobiol Imunol; 2007 Apr; 56(2):51-65. PubMed ID: 17593802
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidemiological and Economic Effects of Priming With the Whole-Cell Bordetella pertussis Vaccine.
    DeAngelis H; Scarpino SV; Fitzpatrick MC; Galvani AP; Althouse BM
    JAMA Pediatr; 2016 May; 170(5):459-65. PubMed ID: 27018830
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of acellular pertussis vaccine in Japan, evaluated by 23 years of its use for routine immunization.
    Kuno-Sakai H; Kimura M
    Pediatr Int; 2004 Dec; 46(6):650-5. PubMed ID: 15660862
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pertussis before and after the introduction of acellular pertussis vaccines in Finland.
    Elomaa A; He Q; Minh NN; Mertsola J
    Vaccine; 2009 Sep; 27(40):5443-9. PubMed ID: 19628060
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Controlling pertussis: how can we do it? A focus on immunization.
    Martinón-Torres F; Heininger U; Thomson A; Wirsing von König CH
    Expert Rev Vaccines; 2018 Apr; 17(4):289-297. PubMed ID: 29482390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A controlled trial of a two-component acellular, a five-component acellular, and a whole-cell pertussis vaccine.
    Gustafsson L; Hallander HO; Olin P; Reizenstein E; Storsaeter J
    N Engl J Med; 1996 Feb; 334(6):349-55. PubMed ID: 8538705
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The cost of epidemiological transition: a study of a decrease in pertussis vaccination coverage.
    Girard DZ
    Health Policy; 2005 Nov; 74(3):287-303. PubMed ID: 15951048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pertussis epidemic despite high levels of vaccination coverage with acellular pertussis vaccine.
    Sala-Farré MR; Arias-Varela C; Recasens-Recasens A; Simó-Sanahuja M; Muñoz-Almagro C; Pérez-Jové J
    Enferm Infecc Microbiol Clin; 2015 Jan; 33(1):27-31. PubMed ID: 24216286
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Do we need a new vaccine to control the re-emergence of pertussis?
    Mills KH; Ross PJ; Allen AC; Wilk MM
    Trends Microbiol; 2014 Feb; 22(2):49-52. PubMed ID: 24485284
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Unexpectedly limited durability of immunity following acellular pertussis vaccination in preadolescents in a North American outbreak.
    Witt MA; Katz PH; Witt DJ
    Clin Infect Dis; 2012 Jun; 54(12):1730-5. PubMed ID: 22423127
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Shift in the epidemiology of pertussis infection: an indication for pertussis vaccine boosters for adults?
    Yeh SH; Mink CM
    Drugs; 2006; 66(6):731-41. PubMed ID: 16706548
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Epidemiology of pertussis in industrialized countries].
    Baron S; Bégué P; Grimprel E
    Sante; 1994; 4(3):195-200. PubMed ID: 7921686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of changing from whole-cell to acellular pertussis vaccine on the epidemiology of hospitalized children with pertussis in Canada.
    Bettinger JA; Halperin SA; De Serres G; Scheifele DW; Tam T
    Pediatr Infect Dis J; 2007 Jan; 26(1):31-5. PubMed ID: 17195702
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Whither pertussis?
    Snelling TL; Waddington CS
    Expert Rev Anti Infect Ther; 2015 Feb; 13(2):145-8. PubMed ID: 25426699
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Acellular pertussis vaccines: a turning point in infant and adolescent vaccination.
    Rappuoli R
    Infect Agents Dis; 1996 Jan; 5(1):21-8. PubMed ID: 8789596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Acellular and whole-cell pertussis vaccines in Japan. Report of a visit by US scientists.
    Noble GR; Bernier RH; Esber EC; Hardegree MC; Hinman AR; Klein D; Saah AJ
    JAMA; 1987 Mar; 257(10):1351-6. PubMed ID: 3820444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 26.